MLMinya Lu

Minya Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minya Lu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • David S. Perlin

    Hackensack Meridian Health

    1 shared publication
  • Fushun Li

    The First Hospital of China Medical University

    1 shared publication
  • Hong He

    The Affiliated Hospital of Qingdao University

    1 shared publication
  • Jiajun Xu

    Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    1 shared publication
  • Jialong Chen

    Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; Department of Respiratory and Critical Care Medicine, Peking Hospital, Beijing, China

    1 shared publication
  • Jing Lin

    Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China

    by Yating Ning, Meng Xiao, David S. Perlin, Yanan Zhao, Minya Lu, Yi Li, Zhengyu Luo, Rongchen Dai, Shengjie Li, Jiajun Xu, et al.

    Candida parapsilosis is becoming a predominant non-albicans cause of invasive candidiasis (IC). Echinocandins are the preferred choice for IC treatment and prophylaxis. Resistance to echinocandins in C. parapsilosis has emerged in several countries, but little is known about the susceptibility profile in China or about mechanisms of resistance. Here, we investigated the echinocandin susceptibilities of 2523 C. parapsilosis isolates collected from China and further explored the resistance mechanism among echinocandin-resistant isolates. Anidulafungin exhibited the highest MICs (MIC50/90, 1 and 2 µg/mL; GM, 0.948 µg/mL), while caspofungin showed better activity (0.5 and 1 µg/mL; 0.498 µg/mL). Significantly higher echinocandin MICs were observed among blood-derived isolates compared to others, especially for caspofungin (GM, 1.348 µg/mL vs 0.478 µg/mL). Isolates from ICU and surgical wards also showed higher MICs. Twenty isolates showed intermediate phenotypes for at least one echinocandin. One was resistant to all three echinocandins, fluconazole and voriconazole, which caused breakthrough IC during long-term exposure to micafungin. WGS revealed this isolate carried a mutation S656P in hotspot1 region of Fks1. Bioinformatics analyses suggested that this mutation might lead to an altered protein conformation. CRISPR Cas9-mediated introduction of this mutation into a reference C. parapsilosis strain increased MICs of all echinocandins 64-fold, with similar results found in the subspecies, C. orthopsilosis and C. metapsilosis. This is the first report of a multi-azole resistant and pan-echinocandin resistant C. parapsilosis isolate, and the identification of a FKS1S656P conferring pan-echinocandin resistance. Our study underscores the necessity of rigorous management of antifungal use and of monitoring for fungal susceptibility.


  • Open Access

    De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients with Candidemia

    by Jing Lin, Menglan Zhou, Jialong Chen, Li Zhang, Minya Lu, Zhengyin Liu